Evidence map›Paper›PMID 41919387›Full record

ArticleCirculation. Arrhythmia and electrophysiology2026

Safety and Chronic Atrial Lesion Formation With a Large-Tip, Contact-Force-Sensing Multipolar Pulsed Field Ablation Catheter: Effect of Application Number in a Porcine Beating Heart Model.

Luigi Di Biase, Jacopo Marazzato, Marco Schiavone, Fengwei Zou, Taylor Spangler, Rahul Bhardwaj, Jonathan Hsu, Assaf Govari, Andreas Altman, Kevin Okarski and 14 more

Abstract read
In one paragraph

Article in Circulation. Arrhythmia and electrophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Luigi Di BiaseDepartment of Cardiology, Montefiore Medical Center, Bronx, NY (L.D.B., J.M., F.Z., D.Y., A.L., X.Z.).ORCID 0000-0001-6508-4047
Jacopo MarazzatoDepartment of Cardiology, Montefiore Medical Center, Bronx, NY (L.D.B., J.M., F.Z., D.Y., A.L., X.Z.).ORCID 0000-0003-1205-5925
Marco SchiavoneMonzino Hospital Milan, Milano, Italy (M.S.).ORCID 0000-0003-0720-3380
Fengwei ZouDepartment of Cardiology, Montefiore Medical Center, Bronx, NY (L.D.B., J.M., F.Z., D.Y., A.L., X.Z.).ORCID 0000-0001-6355-8843
Taylor SpanglerBayside Preclinical Services Inc, Dixon (T. Spangler).ORCID 0009-0009-9394-293X
Rahul BhardwajLoma Linda University Heart Institute (R.B.).ORCID 0000-0001-7734-8660
Jonathan HsuUniversity of California, San Diego (J.H.).ORCID 0000-0002-1523-573X
Assaf GovariBiosense Webster, Irvine, CA (A.G., A.A., K.O., T. Sharma, P.P., C.B., T.T., Q.C., W.M.).ORCID 0009-0006-1912-3184
Andreas AltmanBiosense Webster, Irvine, CA (A.G., A.A., K.O., T. Sharma, P.P., C.B., T.T., Q.C., W.M.).ORCID 0009-0005-5439-357X
Kevin OkarskiBiosense Webster, Irvine, CA (A.G., A.A., K.O., T. Sharma, P.P., C.B., T.T., Q.C., W.M.).ORCID 0009-0006-5767-848X
Tushar SharmaBiosense Webster, Irvine, CA (A.G., A.A., K.O., T. Sharma, P.P., C.B., T.T., Q.C., W.M.).
Paras ParikhBiosense Webster, Irvine, CA (A.G., A.A., K.O., T. Sharma, P.P., C.B., T.T., Q.C., W.M.).ORCID 0009-0003-1744-6375
Christopher BeecklerBiosense Webster, Irvine, CA (A.G., A.A., K.O., T. Sharma, P.P., C.B., T.T., Q.C., W.M.).
Terrence TroutmanBiosense Webster, Irvine, CA (A.G., A.A., K.O., T. Sharma, P.P., C.B., T.T., Q.C., W.M.).
Qi ChenBiosense Webster, Irvine, CA (A.G., A.A., K.O., T. Sharma, P.P., C.B., T.T., Q.C., W.M.).
Hiroshi NakagawaSection of Cardiac Electrophysiology & Pacing, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Cleveland Clinic, OH (H.N.).ORCID 0000-0001-9368-519X
William MaddoxBiosense Webster, Irvine, CA (A.G., A.A., K.O., T. Sharma, P.P., C.B., T.T., Q.C., W.M.).ORCID 0000-0002-5529-3221
Devi NairDepartment of Electrophysiology, St. Bernard's Heart &Vascular Center, Jonesboro, AR (D.N.).ORCID 0000-0001-8253-947X
Sanghamitra MohantyTexas Cardiac Arrhythmia Institute, Austin (S.M., V.M.L.F., A.N.).ORCID 0000-0001-6601-944X
Vincenzo Mirco La FaziaTexas Cardiac Arrhythmia Institute, Austin (S.M., V.M.L.F., A.N.).ORCID 0000-0001-7548-4685
Domingo YnoaDepartment of Cardiology, Montefiore Medical Center, Bronx, NY (L.D.B., J.M., F.Z., D.Y., A.L., X.Z.).
Aung LinDepartment of Cardiology, Montefiore Medical Center, Bronx, NY (L.D.B., J.M., F.Z., D.Y., A.L., X.Z.).
Andrea NataleTexas Cardiac Arrhythmia Institute, Austin (S.M., V.M.L.F., A.N.).ORCID 0000-0002-5487-0728
Xiaodong ZhangDepartment of Cardiology, Montefiore Medical Center, Bronx, NY (L.D.B., J.M., F.Z., D.Y., A.L., X.Z.).ORCID 0000-0002-2856-943X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntegration of catheter-tissue contact force with pulsed field ablation (PFA) dosing is essential for achieving safe and durable lesion formation with contact force sensing catheters in ventricular models. However, data on the use of these catheters for atrial ablation remain limited. This study evaluated the procedural safety and 30-day lesion characteristics of atrial PFA delivered with the OMNYPULSE ablation catheter in a porcine model.

methodsTwelve pigs were randomized to receive either 6 (×6 or Group A) or 12 (×12 or group B) PFA applications per ablation. Following 3-dimensional electroanatomic mapping, PFA was delivered to the right superior and inferior pulmonary veins, cavotricuspid isthmus, right atrial posterior wall, left atrial roof, and mitral annulus. Procedural safety was assessed acutely, and lesion characteristics were evaluated on 30-day histology. Maximum transmurality extent (MTE) was defined as >80% of the lesion span exhibiting continuous endocardial-to-epicardial fibrosis within representative histological sections.

resultsAdequate catheter-tissue contact was achieved during PFA delivery (contact force, 28±15 g). No acute procedural complications were observed. At 30 days, PVs and right atrial sites (ie, cavotricuspid isthmus and right atrial posterior wall) demonstrated near-complete MTE regardless of PFA dosing. In contrast, MTE was significantly lower at the mitral annulus and LA roof compared with other sites (44±30% and 21±26%, respectively;

conclusionsAtrial PFA using the OMNYPULSE catheter was feasible and safe in a porcine model. However, lesion transmurality varied by atrial location and was dose-dependent at select sites, underscoring the need for site-specific PFA dosing strategies. Further studies are warranted to define optimal PFA parameters for consistent atrial lesion formation.

Indexed as

Cardiac CathetersCatheter AblationHeart AtriaPulmonary VeinsAnimalsElectrophysiologic Techniques, CardiacEquipment DesignFemaleFibrosisIrreversible Electroporation TherapyModels, AnimalSus scrofaSwineTime Factorscatheter ablationelectroporationpulmonary veinsafetyswine

Identifiers

PMID41919387
PMCPMC13098655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.